Research Pulse — 2026-10-08 | Brown Biotech

# Research Pulse — 2026-10-08
_Generated 2026-10-08 07:30 KST · AI × Bioresearch Daily synthesis_

Brown Biotech daily research pulse — multi-front synthesis across CRISPR /
gene editing, AI drug discovery, protein AI, single-cell foundation models,
FDA/regulatory, and spatial transcriptomics. Sources: company filings,
peer-reviewed journals, FDA guidance, conference disclosures.

---

### Post 1: 오늘의 전체 흐름

🧬 **AI × Bioresearch Daily — 10월 8일 (수요일) · Maturing(성숙) Day**

10/08(성숙) → 10/07(산업화) → 10/06(산업화) → 10/05(확장) → 10/04(가속) → 10/03(수렴) → 10/02(정착) → 10/01(임상 전환). Industrializing(10/06-10/07)된 기술들이 **제조 공정 표준화·품질 검증 체계 확립·임상 데이터 축적을 통해 산업적 성숙(Maturing)의 단계로 진입하는 날** — Haldrup et al.로 LVNPs(Lentivirus-derived nanoparticles) CRISPR/Cas RNP 전달 체계 확립 — base editing·prime editing 모두 가능 + in vivo mouse eye proof-of-concept 확인(Nucleic Acids Research 2023), Chen et al.로 LLM molecular design evolution — chemical syntax와 biological semantics bridging + de novo hit identification + multimodal frameworks + autonomous DMTA cycles(Drug Discovery Today 2026), Yin et al.로 AlphaFold3 drug discovery 적용 종합 — ESMFold 속도/확장성 + drug discovery/enzyme engineering/disease research 적용 + current challenges 분석(Frontiers in Molecular Biosciences 2026), Wei et al.로 sc perturbation 27 methods benchmarking — PerturbNet이 DE signatures 최고이나 cross-cell type generalization 실패 확인 + cell context embedding 필요성(Nature Methods 2025), Ahlmann-Eltze et al.로 deep learning perturbation prediction이 simple linear baselines 능가하지 못함 확인 — 5개 foundation models 모두 실패(Nature Methods 2025), Cetin et al.로 CRISPR gene therapy 임상 trials 현황 — Casgevy FDA 승인(2023) 현실 + SCD/TDT 임상 데이터 축적 + HIV/cancer 치료 가능성(Expert Reviews Molecular Medicine 2025), Gao et al.로 gastric cancer LAR atlas 재확인 — CD70+LAMP3+ DCs + PD1+CD27+CD8 T cells 근접성 + immunotherapy biomarker(Nature Communications 2026), Li et al.로 HiST deep learning spatial transcriptomics reconstruction — histology images에서 spatial GEPs 예측 + 5개 암종 AUC 0.96 + Pearson 0.74 + TCGA prognostic stratification 확인(Advanced Science 2026)이 동시에 진행된다.

Maturing은 Industrializing의 다음 단계다. 오늘 6개 전선은 산업화된 기술들이 **제조 공정 표준화·품질 검증 체계 확립·임상 데이터 축적으로 성숙(Maturing)하는 날**이다.

*출처: [Haldrup LVNPs CRISPR RNP Nucleic Acids Research 2023](https://consensus.app/papers/details/988a44b8b89e5d03a67fd82b85cebcd7/), [Chen LLM Molecular Design Drug Discovery Today 2026](https://consensus.app/papers/details/6d5447b842e65298b7932fe7c4bf3e3c/), [Yin AlphaFold3 Applications Frontiers Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/), [Wei Perturbation Benchmark Nature Methods 2025](https://consensus.app/papers/details/2252f23023815170ad69618a33936f87/), [Ahlmann-Eltze Deep Learning Perturbation Nature Methods 2025](https://consensus.app/papers/details/a48c95b391f25de2813ae2d2bc322524/), [Cetin CRISPR Clinical Trials Expert Reviews Molecular Medicine 2025](https://consensus.app/papers/details/7e3e6068dcc7526f92d729fcd73cd99d/), [Gao Gastric Cancer LAR Atlas Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/), [Li HiST Spatial Transcriptomics Advanced Science 2026](https://consensus.app/papers/details/5dfa277e84425924aac9d148317c0bb7/)*

*#MaturingDay #Haldrup #LVNPs #LentivirusNanoparticles #CRISPR #RNP #BaseEditing #PrimeEditing #InVivo #Chen #LLM #MolecularDesign #DrugDiscovery #ChemicalSyntax #BiologicalSemantics #DMTA #Autonomous #Yin #AlphaFold3 #ESMFold #Frontiers #MolecularBiosciences #Wei #PerturbationBenchmark #PerturbNet #NatureMethods #AhlmannEltze #DeepLearning #LinearBaselines #NoOutperformance #Cetin #CRISPR #ClinicalTrials #Casgevy #SCD #TDT #ExpertReviews #Gao #LAR #GastricCancer #NatureCommunications #Li #HiST #SpatialTranscriptomics #DeepLearning #Histology #AdvancedScience #Maturing #Industrializing #ManufacturingStandardization #QualityValidation #ClinicalData #BiomedicalAI #DailyReport*

---

### Post 2: CRISPR & Gene Editing — LVNPs RNP Delivery × Clinical Trials × Cardiovascular Manufacturing: Maturing

🪄 **[CRISPR/Gene Editing] Haldrup et al.로 LVNPs(Lentivirus-derived nanoparticles) CRISPR/Cas RNP 전달 체계 확립 — base editing·prime editing 모두 가능 + in vivo mouse eye proof-of-concept 확인(Nucleic Acids Research 2023) + Cetin et al.로 CRISPR gene therapy 임상 trials 현황 — Casgevy FDA 승인(2023) + SCD/TDT 임상 데이터 축적 + HIV/cancer 치료 가능성(Expert Reviews Molecular Medicine 2025) + Fakiyesi et al.로 CRISPR inherited cardiovascular diseases 적용 체계적 review 재확인 — 7개 질환 카테고리 + cardiomyocytes 재생 한계 + 게놱 수정 안전성 + 심장نسي세포 특이적 전달 필요성(Cureus 2026): CRISPR Maturing(성숙) 동시 확인**

CRISPR gene therapy의 **비바이러스성 RNP 전달 체계 확립 + 임상 trials 현황 + 심혈관 질환 적용 과제(Maturing)**가 출처에서 동시에 확인된다[1][2][3].

**LVNPs: Lentivirus-Derived Nanoparticles RNP 전달 체계 확립[1]**
J. Haldrup et al.(Nucleic Acids Research 2023)의 연구는 lentivirus-derived nanoparticles(LVNPs)로 CRISPR/Cas ribonucleoprotein(RNP) 복합체 전달 체계를 제시한다[1]. **핵심 혁신**: LVNPs가 기존 viral vectors와 non-viral vectors의 한계를 동시에 극복. Gag/GagPol fusion proteins로 RNP packaging 최적화. **Base editing + prime editing 모두 가능**: SpCas9 BE/sgRNA와 PE/epegRNA RNPs 모두 전달 가능. **In vivo mouse eye proof-of-concept**: LVNP-directed in vivo gene disruption 최초 입증. **빠른ター닝**: near-instantaneous target DNA cleavage + 4일 내 완전한 RNP turnover. **Off-target 감소**: 표준 nucleofection 대비 lower off-target cleavage. **DSB-independent editing**: indel formation 없이 prime editing 가능. 핵심: LVNPs로 CRISPR/Cas RNP 전달 체계 확립 — 비바이러스성 전달의 성숙.

**CRISPR Gene Therapy 임상 Trials 현황: Casgevy FDA 승인 현실[2]**
Busra Cetin et al.(Expert Reviews in Molecular Medicine 2025)의 review는 CRISPR gene therapy의 임상 trials 현황을 종합한다[2]. **Casgevy FDA 승인(2023)**: BCL11A-enhancer 편집으로 자가 조혈줄기세포 유전자치료. SCD와 TDT 환자 대상. **현재 임상 trials**: sickle cell disease(SCD), transfusion-dependent beta-thalassaemia(TDT), HIV, cancer 등 다양한 질환 적용. **향후 prospects**: CRISPR technology의 치료 잠재력 확인했으나 off-target effects, delivery systems, long-term safety, scalability, ethical dilemmas 극복 필요. 핵심: CRISPR gene therapy 임상 trials 현황 — FDA 승인 이후 현실적 도전 과제.

**CRISPR 심혈관 질환 적용: 전달 특이성 과제 재확인[3]**
Tolulope Fakiyesi et al.(Cureus 2026)의 review는 CRISPR의 inherited cardiovascular diseases 적용을 재확인한다[3]. **7개 질환 카테고리**: inherited cardiomyopathies, arrhythmic disorders, vascular diseases, lipid disorders, metabolic cardiac conditions, cardiac developmental disorders, systemic disorders affecting heart. **cardiomyocytes 재생 한계**: 성체 심장의 제한적 재생 능력. **게놱 수정 안전성 문제**: off-target effects와 large-scale chromosomal rearrangements. **심장نسي세포 특이적 전달 필요성**: skeletal muscle과 CNS처럼 심장에 도달하는 효율적 전달 체계 필요. 핵심: CRISPR 심혈관 질환 적용의 전달 특이성 과제 — 심장 특이적 전달 체계의 성숙 필요.

**10월 7일 Industrializing(DeWitt CRISPR_SCD001 manufacturing + Bashir clinical translation + Fakiyesi cardiovascular) vs 오늘의 차별점**: 10/07이 **DeWitt Molecular Therapy**으로 CRISPR_SCD001 Phase I trial 착수를, **Bashir Frontiers Genome Editing**으로 CRISPR-Cas9 임상 전환 포괄적 review를, **Fakiyesi Cureus**으로 심혈관 질환 적용을 제시했다면, 오늘은 **Haldrup Nucleic Acids Research**으로 **LVNPs RNP 전달 체계 확립**이라는 새로운 전달 기술 관점(Maturing)을, **Cetin Expert Reviews**으로 **Casgevy FDA 승인 이후 임상 trials 현실**을(승인 후 성숙), **Fakiyesi 재확인**으로 **심장نسي세포 특이적 전달 필요성**을(전달 특이성 성숙 과제) 동시에 제시한다. Industrializing(10/07) → LVNPs 전달 체계 확립 + 임상 trials 현황 + 전달 특이성 과제 Maturing(10/08).

실무 함의: 유전자 치료 전달 기술팀에서 Haldrup et al.의 LVNPs 접근법을 비바이러스성 전달 전략에 반영해야 한다.

*출처: [Haldrup LVNPs CRISPR RNP Delivery Nucleic Acids Research 2023](https://consensus.app/papers/details/988a44b8b89e5d03a67fd82b85cebcd7/), [Cetin CRISPR Clinical Trials Expert Reviews Molecular Medicine 2025](https://consensus.app/papers/details/7e3e6068dcc7526f92d729fcd73cd99d/), [Fakiyesi CRISPR Cardiovascular Cureus 2026](https://consensus.app/papers/details/a52297053cfa5471bfa03ab5f8f01db4/)*

*#CRISPR #GeneEditing #Haldrup #LVNPs #LentivirusNanoparticles #NucleicAcidsResearch #RNP #BaseEditing #PrimeEditing #InVivo #GagPol #Cetin #ExpertReviews #MolecularMedicine #Casgevy #FDAApproval #SCD #TDT #ClinicalTrials #HIV #Cancer #Fakiyesi #Cureus #Cardiovascular #InheritedDisease #Cardiomyocytes #Delivery #Specificity #MaturingDay #NonViralDelivery #RNPDelivery #Manufacturing #ClinicalTrials #BiomedicalAI #DailyReport*

---

### Post 3: AI 신약 — LLM Molecular Design Evolution × Perturbation Benchmark × No Deep Learning Outperformance: Maturing

💊 **[AI 신약] Chen et al.로 LLM molecular design evolution — chemical syntax와 biological semantics bridging + de novo hit identification + multi-objective optimization + multimodal frameworks + autonomous DMTA cycles(Drug Discovery Today 2026) + Wei et al.로 sc perturbation 27 methods benchmarking — PerturbNet DE signatures 최고 + cross-cell type generalization 실패 + cell context embedding 필요성(Nature Methods 2025) + Ahlmann-Eltze et al.로 deep learning perturbation prediction이 simple linear baselines 능가하지 못함 확인 — 5개 foundation models 모두 실패(Nature Methods 2025): AI Drug Discovery Maturing(성숙) 동시 확인**

AI-Driven Drug Discovery의 **LLM molecular design 현실 + perturbation prediction benchmarking 현실(Maturing)**이 출처에서 동시에 확인된다[4][5][6].

**LLM Molecular Design: Chemical Syntax Bridging + Autonomous DMTA[4]**
Yingjun Chen et al.(Drug Discovery Today 2026)의 review는 LLM molecular design의 evolution을 분석한다[4]. **chemical syntax와 biological semantics bridging**: LLM이 분자 표현과 생물학적 기능 사이의 격차를 해소. **De novo hit identification**: novel molecules 생성 능력. **Multi-objective optimization**: potency, selectivity, PK 동시 최적화. **Multimodal frameworks**: 3D geometric constraints 통합으로 1D representations의 한계 극복. **Autonomous DMTA cycles**: design-make-test-analyze 순환 자동화. **Persistent disparity**: computational benchmarks와 experimental reality 사이의 격차가 지속됨. **향후 방향**: hybrid neuro-symbolic architectures + unified foundation models. 핵심: LLM molecular design evolution + autonomous DMTA — 설계 자동화 성숙.

**sc Perturbation Benchmarking: PerturbNet 최고 + Generalization 실패[5]**
Zhiting Wei et al.(Nature Methods 2025)의 연구는 27개 perturbation prediction methods를 29개 datasets에서 benchmarking한다[5]. **PerturbNet이 Task 1과 2에서 DE signatures 최고 성능**: differential expression signatures recovery에서 우위. **Cross-cell type generalization 실패**: Task 3에서 어떤 방법도 cross-cell type generalization에 일관되게 성공하지 못함. **Biological consistency dominating**: cross-cell type 상황에서는 biological consistency가 outcomes 결정. **핵심 필요**: cellular context embedding approaches로 generalizability 향상. 핵심: perturbation prediction 27 methods benchmarking — PerturbNet 최고이나 generalization 실패 확인.

**Deep Learning Perturbation: Linear Baselines 능가하지 못함[6]**
C. Ahlmann-Eltze et al.(Nature Methods 2025)의 연구는 deep learning perturbation prediction의 실제 성능을 분석한다[6]. **5개 foundation models + 2개 deep learning models vs simple baselines 비교**: none outperformed. **핵심 발견**: deep learning 기반 foundation models가 simple linear baselines보다 성능이 뛰어나지 않음. **Implication**: critical benchmarking의 중요성 강조 + method development 평가에서 기준模型的 필요성. 핵심: deep learning perturbation prediction이 linear baselines 능가하지 못함 — 성숙 단계의 한계 인식.

**10월 7일 Industrializing(Singh AlphaFold limitation + Mao Phase IIa + Seyhan molecular generation) vs 오늘의 차별점**: 10/07이 **Singh Current Opinion**으로 AlphaFold limitation hierarchical framework를, **Mao Frontiers Pharmacology**으로 Phase IIa efficacy를, **Seyhan Critical Reviews**으로 0건 완전 마케팅 승인을 제시했다면, 오늘은 **Chen Drug Discovery Today**으로 **LLM molecular design evolution + autonomous DMTA**를(설계 자동화 성숙), **Wei Nature Methods**으로 **PerturbNet DE 최고이나 cross-cell type generalization 실패**를(benchmarking 성숙), **Ahlmann-Eltze Nature Methods**으로 **5개 foundation models 모두 linear baselines 능가하지 못함**을(기술 성숙 한계) 동시에 제시한다. Industrializing(10/07) → LLM design evolution + benchmarking 현실 + deep learning 한계 인식 Maturing(10/08).

실무 함의: AI drug discovery 팀에서 Chen et al.의 autonomous DMTA 전략을 참조하여 design automation strategy를 수립해야 한다.

*출처: [Chen LLM Molecular Design Drug Discovery Today 2026](https://consensus.app/papers/details/6d5447b842e65298b7932fe7c4bf3e3c/), [Wei Perturbation Benchmark Nature Methods 2025](https://consensus.app/papers/details/2252f23023815170ad69618a33936f87/), [Ahlmann-Eltze Deep Learning Perturbation Nature Methods 2025](https://consensus.app/papers/details/a48c95b391f25de2813ae2d2bc322524/)*

*#AI #DrugDiscovery #Chen #DrugDiscoveryToday #LLM #MolecularDesign #ChemicalSyntax #BiologicalSemantics #DMTA #Autonomous #DeNovo #HitIdentification #MultiObjective #Wei #PerturbationBenchmark #NatureMethods #PerturbNet #27Methods #29Datasets #CrossCellType #Generalization #CellContext #AhlmannEltze #DeepLearning #LinearBaselines #NoOutperformance #5FoundationModels #MaturingDay #DesignAutomation #BenchmarkingReality #TechnologyLimitations #BiomedicalAI #DailyReport*

---

### Post 4: 단백질 AI — AlphaFold3 Applications × ESMFold × Drug Discovery Frontiers: Maturing

🔬 **[단백질 AI] Yin et al.로 AlphaFold3 applications 종합 — ESMFold 속도/확장성 + drug discovery/enzyme engineering/disease research 적용 + current challenges(Frontiers in Molecular Biosciences 2026) + Abramson et al.로 AlphaFold3 protein-nucleic acid interactions + protein-ligand interactions大幅 개선(Nature 2024) + Chakraborty et al.로 AF1→AF2→AF3 evolution + SBDD accelerated(Nature Biotechnology 2026): 단백질 AI Maturing(성숙) 동시 확인**

단백질 AI의 **AlphaFold3 적용 종합 + ESMFold 속도/확장성 + SBDD 가속화(Maturing)**가 출처에서 동시에 확인된다[7][8][9].

**AlphaFold3 Applications 종합: ESMFold 속도/확장성 + Drug Discovery 적용[7]**
Tianxiang Yin et al.(Frontiers in Molecular Biosciences 2026)의 review는 AI-driven protein structure prediction의 적용을 종합한다[7]. **ESMFold**: single-sequence approach로 속도와 확장성 크게 향상. **AlphaFold3**: Evoformer 대신 Pairformer 사용. **적용 영역**: drug discovery — 단백질-리간드 상호작용 예측, enzyme engineering — 효소 촉매 효율 최적화, disease research — 질환 관련 단백질 구조 분석. **Current challenges**: protein dynamics modeling, incomplete annotation, conformational flexibility. **향후 방향**: enhanced accuracy + expanded applicability. 핵심: AlphaFold3 applications 종합 + ESMFold 속도/확장성 — 단백질 AI 적용 성숙.

**AlphaFold3 Protein-Nucleic Acid + Protein-Ligand Interactions大幅改善[8]**
Josh Abramson et al.(Nature 2024)의 연구는 AlphaFold3의 성능 향상을 분석한다[8]. **Protein-ligand interactions**: state-of-the-art docking tools 대비大幅 개선. **Protein-nucleic acid interactions**: nucleic-acid-specific predictors 대비 크게 향상. **Antibody-antigen prediction**: AlphaFold-Multimer v2.37 대비 현저히 향상. **단일 unified framework**: proteins, nucleic acids, small molecules, ions, modified residues 모두 예측 가능. 핵심: AlphaFold3 protein-nucleic acid + protein-ligand interactions大幅改善 — 단백질 AI 성숙.

**AlphaFold Evolution: AF1→AF2→AF3 + SBDD Accelerated[9]**
Chakraborty, Bhattacharya & Lee(Nature Biotechnology 2026)의 review는 AlphaFold evolution을 재확인한다[9]. AF1(DNN) → AF2(Evoformer) → AF3(Pairformer). 2024 Nobel Prize로 protein structure prediction 인정. SBDD가加速되었으나 protein dynamics + multiple conformational states 예측 도전과제 남음. 핵심: AlphaFold evolution + SBDD 가속화 — 단백질 AI 산업 성숙.

**10월 7일 Industrializing(Singh AlphaFold limitation + Chakraborty AF3 + Iglesias-López CGT quality) vs 오늘의 차별점**: 10/07이 **Singh Current Opinion**으로 AlphaFold limitation hierarchical framework를, **Chakraborty Nature Biotechnology**으로 AF3 evolution을, **Iglesias-López Therapeutic Innovation**으로 EU-US CGT quality를 제시했다면, 오늘은 **Yin Frontiers Molecular Biosciences**으로 **ESMFold 속도/확장성 + drug discovery/enzyme engineering/disease research 적용 종합**이라는 포괄적 적용 관점(Maturing)을, **Abramson Nature**으로 **AlphaFold3 protein-nucleic acid + protein-ligand大幅改善**를(성능 성숙), **Chakraborty 재확인**으로 **AF3 evolution + SBDD 가속화**를(산업 성숙) 동시에 제시한다. Industrializing(10/07) → 적용 종합 + 성능 개선 + SBDD 가속화 Maturing(10/08).

실무 함의: 단백질 AI 팀에서 Yin et al.의 ESMFold 적용 결과를 참조하여 structure-based drug design strategy를 수립해야 한다.

*출처: [Yin AlphaFold3 Applications Frontiers Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/), [Abramson AlphaFold3 Nature 2024](https://consensus.app/papers/details/48c459ae935b59ea9a75d3647ba7d47b/), [Chakraborty AlphaFold3 Nature Biotechnology 2026](https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/)*

*#ProteinAI #AlphaFold #Yin #Frontiers #MolecularBiosciences #ESMFold #Speed #Scalability #DrugDiscovery #EnzymeEngineering #DiseaseResearch #Abramson #Nature #AlphaFold3 #ProteinLigand #ProteinNucleicAcid #ImprovedAccuracy #Chakraborty #NatureBiotechnology #Evolution #SBDD #Accelerated #NobelPrize #MaturingDay #ApplicationMaturation #PerformanceImprovement #BiomedicalAI #DailyReport*

---

### Post 5: Single-Cell Multi-Omics Foundation Model — Perturbation Benchmarking × No Deep Learning Outperformance × Confidence Audit: Maturing

🬬 **[Single-Cell Multi-Omics Foundation Model] Wei et al.로 sc perturbation 27 methods benchmarking — PerturbNet DE signatures 최고 + cross-cell type generalization 실패 + cell context embedding 필요성(Nature Methods 2025) + Ahlmann-Eltze et al.로 deep learning perturbation prediction이 simple linear baselines 능가하지 못함 확인 — 5개 foundation models 모두 실패(Nature Methods 2025) + Weng et al.로 frozen scFM confidence audit framework 재확인 — raw MSP 불신뢰 + rank-ordering errors + probability drift + recalibration 필요(bioRxiv 2026): foundation model Maturing(성숙) 동시 확인**

Single-Cell Foundation Model의 **perturbation benchmarking 현실 + deep learning 한계 + confidence reliability 과제(Maturing)**가 출처에서 동시에 확인된다[5][6][10].

**Perturbation Benchmarking: PerturbNet 최고 + Cross-Cell Type Generalization 실패[5]**
(Zhang Wei et al. — Post 3에서 상세 기술). PerturbNet이 DE signatures에서 최고이나 cross-cell type generalization 실패. **Cell context embedding 필요성** 강조. 핵심: perturbation benchmarking 현실 — benchmark 성숙.

**Deep Learning No Outperformance: Linear Baselines Baseline[6]**
(C. Ahlmann-Eltze et al. — Post 3에서 상세 기술). 5개 foundation models 모두 simple linear baselines 능가하지 못함. **Critical benchmarking의 중요성** 강조. 핵심: deep learning perturbation prediction의 한계 — 기술 성숙 한계.

**Frozen scFM Confidence Audit: MSP 불신뢰 + Recalibration 필요[10]**
Guang-Zheng Weng et al.(bioRxiv 2026)의 연구를 재확인한다[10]. **Raw MSP 불신뢰**: source-target confidence 불일치로 신뢰 불가. **Rank-ordering errors**: 확률 drift 분리 필요. **Recalibration 전략**: small labeled target data로 drift recalibration 가능. **Safe deployment 조건**: representative local labels로 target-specific confidence adjustment 필수. 핵심: frozen scFM confidence audit framework — deployment reliability 성숙 과제.

**10월 7일 Industrializing(Liu Gene-Chronos + Weng confidence audit + DenAdel plateau) vs 오늘의 차별점**: 10/07이 **Liu Briefings in Bioinformatics**으로 Gene-Chronos temporal inference를, **Weng bioRxiv**으로 frozen scFM confidence audit를, **DenAdel Nature Methods**으로 scaling law plateau를 제시했다면, 오늘은 **Wei Nature Methods**으로 **27 methods perturbation benchmark에서 PerturbNet 최고이나 cross-cell type generalization 실패**라는 benchmarking 성숙 현실(Benchmarking Maturation)을, **Ahlmann-Eltze Nature Methods**으로 **5개 foundation models 모두 linear baselines 능가하지 못함**이라는 기술 한계(Maturation Limit)를, **Weng 재확인**으로 **MSP 불신뢰 + recalibration 필요**이라는 deployment reliability 성숙 과제(Deployment Maturation)를 동시에 제시한다. Industrializing(10/07) → benchmarking 현실 + deep learning 한계 + confidence reliability 과제 Maturing(10/08).

실무 함의: 단일세포 연구팀에서 Weng et al.의 confidence audit framework를 참조하여 scFM deployment reliability strategy를 수립해야 한다.

*출처: [Wei Perturbation Benchmark Nature Methods 2025](https://consensus.app/papers/details/2252f23023815170ad69618a33936f87/), [Ahlmann-Eltze Deep Learning Perturbation Nature Methods 2025](https://consensus.app/papers/details/a48c95b391f25de2813ae2d2bc322524/), [Weng Frozen scFM Confidence Audit bioRxiv 2026](https://consensus.app/papers/details/530d9bca4dcd5352a22a7358413c9999/)*

*#SingleCell #FoundationModel #Wei #PerturbationBenchmark #NatureMethods #PerturbNet #27Methods #29Datasets #CrossCellType #GeneralizationFailure #CellContext #AhlmannEltze #DeepLearning #LinearBaselines #NoOutperformance #5FoundationModels #Weng #ConfidenceAudit #MSP #ProbabilityDrift #Recalibration #MaturingDay #BenchmarkingMaturation #TechnologyLimitations #DeploymentReliability #BiomedicalAI #DailyReport*

---

### Post 6: FDA/규제 — CRISPR Therapeutics Approval × CGT Manufacturing Comparability × Platform-Aligned AI/ML: Maturing

📋 **[FDA/규제] Cetin et al.로 CRISPR gene therapy 임상 trials 현황 — Casgevy FDA 승인(2023) + SCD/TDT 임상 데이터 축적 + HIV/cancer 치료 가능성(Expert Reviews Molecular Medicine 2025) + Chakraborty et al.로 CRISPR-Cas9 therapeutics approval landscape — Casgevy UK/MHRA 승인(2023) + FDA 승인(2023) + clinical trials 현황(Molecular Therapy Nucleic Acids 2026) + Oo et al.로 FDA platform-aligned AI/ML analytics — dose selection·safety evaluation·durability prediction convergence 재확인(J Clinical Pharmacology 2026): FDA/규제 Maturing(성숙) 동시 확인**

FDA 규제 영역의 **CRISPR 치료제 승인 현실 + CGT manufacturing quality + AI/ML regulatory convergence(Maturing)**가 출처에서 동시에 확인된다[2][11][12].

**CRISPR Gene Therapy Approval Landscape: Casgevy 현실[2]**
(Busra Cetin et al. — Post 2에서 상세 기술). 핵심: CRISPR gene therapy 임상 trials 현황 — FDA 승인 이후 현실.

**CRISPR-Cas9 Therapeutics Approval Landscape: Casgevy UK/MHRA + FDA[11]**
Chakraborty et al.(Molecular Therapy. Nucleic Acids 2026)의 review는 CRISPR-Cas9 therapeutics의 승인 현황을 분석한다[11]. **Casgevy UK/MHRA 승인(2023.11)**: TDT 치료를 위한 최초 승인. **Casgevy FDA 승인(2023.12)**: SCD 치료를 위한 최초 CRISPR 치료제. **BCL11A-enhancer 편집**: 자가 조혈줄기세포 유전자치료. **향후 pipelines**: HIV 치료, cancer 치료 등 활발한 연구 진행. 핵심: CRISPR-Cas9 therapeutics approval landscape — 최초 승인 이후 현실.

**FDA Platform-Aligned AI/ML Analytics Convergence 재확인[12]**
C. Oo et al.(J Clinical Pharmacology 2026)을 재확인한다[12]. **Platform-aligned, risk-based approach**: plausible mechanism framework, CMC flexibility, advanced manufacturing. **AI/ML analytics**: dose selection, safety evaluation, durability prediction 지원 확대. **Individualized, mechanistically targeted, potentially curative products** 지원. 핵심: FDA platform-aligned AI/ML analytics convergence — 규제-기술 통합 성숙.

**10월 7일 Industrializing(Iglesias-López EU-US CGT quality + Oo platform + Shahzad approval) vs 오늘의 차별점**: 10/07이 **Iglesias-López Therapeutic Innovation**으로 manufacturing comparability bottleneck을, **Oo J Clinical Pharmacology**으로 platform-aligned를, **Shahzad Clinical Pharmacology**으로 86.8% orphan을 제시했다면, 오늘은 **Cetin Expert Reviews**으로 **Casgevy FDA 승인 이후 임상 trials 현황**이라는 승인 후 현실(Approval Maturation)을, **Chakraborty Molecular Therapy Nucleic Acids**으로 **Casgevy UK/MHRA + FDA dual approval 현실**을(승인 현실 성숙), **Oo 재확인**으로 **AI/ML analytics dose selection·safety·durability convergence**를(규제-기술 통합 성숙) 동시에 제시한다. Industrializing(10/07) → Casgevy 승인 현실 + manufacturing comparability + AI/ML convergence Maturing(10/08).

실무 함의: Regulatory Affairs팀에서 Cetin et al.의 Casgevy 승인 이후 데이터를 gene therapy regulatory strategy에 반영해야 한다.

*출처: [Cetin CRISPR Clinical Trials Expert Reviews Molecular Medicine 2025](https://consensus.app/papers/details/7e3e6068dcc7526f92d729fcd73cd99d/), [Chakraborty CRISPR Therapeutics Approval Molecular Therapy Nucleic Acids 2026](https://consensus.app/papers/details/68148f0062ec554ba4af1996dd3718cb/), [Oo FDA Platform AI Analytics J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/)*

*#FDA #GeneTherapy #Cetin #ExpertReviews #MolecularMedicine #Casgevy #FDAApproval #MHRA #SCD #TDT #BCL11A #ClinicalTrials #HIV #Cancer #Chakraborty #MolecularTherapyNucleicAcids #CRISPR #Cas9 #Therapeutics #Approval #Landscape #Oo #JClinicalPharmacology #PlatformAligned #AI #ML #Analytics #DoseSelection #SafetyEvaluation #DurabilityPrediction #MaturingDay #ApprovalMaturation #ManufacturingComparability #RegTechConvergence #BiomedicalAI #DailyReport*

---

### Post 7: Spatial Transcriptomics — HiST Deep Learning Reconstruction × LAR Atlas × Pan-Cancer Niche: Maturing

🗺️ **[Spatial Transcriptomics] Li et al.로 HiST(Histological Images Spatial Transcriptomics) deep learning framework — histology images에서 spatial GEPs prediction + 5개 암종 AUC 0.96 + Pearson 0.74 + TCGA prognostic stratification(Advanced Science 2026) + Gao et al.로 gastric cancer LAR atlas 재확인 — CD70+LAMP3+ DCs + PD1+CD27+CD8 T cells 근접성 + immunotherapy biomarker(Nature Communications 2026) + Li et al.로 pan-cancer 56 LCPs + 13 niches + Niche_4 poor prognosis + Niche_11 better survival 재확인(Cell Reports Medicine 2026): spatial transcriptomics Maturing(성숙) 동시 확인**

Spatial transcriptomics의 **deep learning histology reconstruction + LAR atlas + niche survival analysis(Maturing)**가 출처에서 동시에 확인된다[13][14][15].

**HiST: Deep Learning Spatial Transcriptomics Reconstruction[13]**
Wei Li et al.(Advanced Science 2026)의 연구는 HiST(Histological Images Reconstruct Tumor Spatial Transcriptomics)를 제시한다[13]. **방법**: multi-scale convolutional deep learning framework로 ST의 spatially resolved gene expression profiles(GEPs)와 histological morphology 사이의 관계를 학습. **Histology images에서 spatial GEPs prediction**: 조직 슬라이드 이미지만으로 공간적 유전자 발현 프로파일 예측. **5개 암종 AUC 0.96**: breast cancer 포함 다수 암종에서 높은 정확도. **Pearson correlation 0.74**: 예측된 GEPs와 실제 ST 데이터 사이의 상관관계. **TCGA prognostic stratification**: 예측된 GEPs로 환자 예후分层 가능. **Implications**: 종양 이질성 평가, 면역치료 반응 예측, 생물학적 경로 분석. 핵심: HiST deep learning spatial transcriptomics reconstruction — 조직학 이미지의학 적용 성숙.

**Gastric Cancer LAR Atlas 재확인: Immunotherapy Biomarker[14]**
Sen Gao et al.(Nature Communications 2026)을 재확인한다[14]. **CD70+LAMP3+ dendritic cells와 PD1+CD27+CD8 T cells의 공간적 근접성**: immunotherapy response 예측 biomarker. **Naïve T cell abundance와 T cell activation pathways 상관관계**. 핵심: gastric cancer LAR atlas + immunotherapy biomarker — 면역 치료표적 성숙.

**Pan-Cancer 56 LCPs + 13 Niches 재확인: Niche Survival Analysis[15]**
Jiarong Li et al.(Cell Reports Medicine 2026)을 재확인한다[15]. **Niche_4(macrophage + tumor cell)**: poor prognosis + immunotherapy resistance. **Niche_11(macrophage + immune cell)**: better survival + treatment response. **Ligand-receptor analysis**: niche-shared + niche-specific interactions. 핵심: pan-cancer niche survival analysis — 생체표적 성숙.

**10월 7일 Industrializing(Gao LAR atlas + Li 56 LCPs + Zhang SCLC) vs 오늘의 차별점**: 10/07이 **Gao Nature Communications**으로 LAR atlas를, **Li Cell Reports Medicine**으로 Niche_4/Niche_11을, **Zhang Cell Reports Medicine**으로 PIHs-1을 제시했다면, 오늘은 **Li Advanced Science**으로 **HiST deep learning histology images에서 spatial GEPs prediction**이라는 새로운 reconstruction 기술(Histological Reconstruction Maturation)을, **Gao 재확인**으로 **LAR + immunotherapy biomarker**를(면역 치료표적 성숙), **Li pan-cancer 재확인**으로 **Niche_4/Niche_11 survival prediction**을(생체표적 성숙) 동시에 제시한다. Industrializing(10/07) → HiST deep learning reconstruction + LAR biomarker + niche survival Maturing(10/08).

실무 함의: 면역종양학팀에서 Li et al.의 HiST 접근법을 histopathology 기반 spatial prediction에 적용해야 한다.

*출처: [Li HiST Spatial Transcriptomics Advanced Science 2026](https://consensus.app/papers/details/5dfa277e84425924aac9d148317c0bb7/), [Gao Gastric Cancer LAR Atlas Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/), [Li Pan-Cancer Niche Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)*

*#SpatialTranscriptomics #Li #HiST #AdvancedScience #DeepLearning #Histology #Images #SpatialGEPs #Prediction #AUC #Pearson #TCGA #PrognosticStratification #Gao #LAR #GastricCancer #NatureCommunications #PD1 #CD27 #CD8 #CD70 #LAMP3 #DCs #Immunotherapy #Biomarker #Li #PanCancer #56LCPs #13Niches #Niche4 #Niche11 #Macrophage #Tumor #Prognosis #MaturingDay #HistologicalReconstruction #ImmunotherapyBiomarker #SurvivalPrediction #BiomedicalAI #DailyReport*

---

### Post 8: 오늘의 요약 — Maturing(성숙) Day 핵심 정리

🧬 **오늘 6개 영역 핵심 요약:**

10/08(Maturing)의 핵심: Industrializing(10/07)된 기술들이 **제조 공정 표준화·품질 검증 체계 확립·임상 데이터 축적으로 산업적 성숙(Maturing)의 단계로 진입하는 날**이었다.

**1. LVNPs CRISPR/Cas RNP Delivery 체계 확립(Haldrup Nucleic Acids Research 2023)**: Lentivirus-derived nanoparticles로 base editing + prime editing 모두 가능 + in vivo mouse eye proof-of-concept 확인 + off-target 감소 — 비바이러스성 전달 성숙[1].

**2. Casgevy FDA 승인 이후 CRISPR Gene Therapy 임상 Trials 현황(Cetin Expert Reviews Molecular Medicine 2025)**: Casgevy FDA 승인(2023) 현실 + SCD/TDT 임상 데이터 축적 + HIV/cancer 치료 가능성 — 임상 적용 성숙[2].

**3. LLM Molecular Design Evolution + Autonomous DMTA(Chen Drug Discovery Today 2026)**: chemical syntax와 biological semantics bridging + de novo hit identification + multimodal frameworks + autonomous DMTA cycles — 설계 자동화 성숙[4].

**4. Perturbation Benchmarking PerturbNet 최고 + Generalization 실패(Wei Nature Methods 2025 + Ahlmann-Eltze Nature Methods 2025)**: PerturbNet이 DE signatures 최고이나 cross-cell type generalization 실패; 5개 foundation models 모두 linear baselines 능가하지 못함 — benchmarking 현실 인식 성숙[5][6].

**5. AlphaFold3 Protein-Nucleic Acid + Protein-Ligand Interactions大幅改善(Abramson Nature 2024)**: docking tools 대비大幅 개선 + nucleic-acid-specific predictors 대비 향상 + antibody-antigen prediction 향상 — 단백질 AI 성능 성숙[8].

**6. HiST Deep Learning Spatial Transcriptomics Reconstruction(Li Advanced Science 2026)**: histology images에서 spatial GEPs prediction + 5개 암종 AUC 0.96 + Pearson 0.74 + TCGA prognostic stratification — 조직학 기반 spatial prediction 성숙[13].

10월 9일 전망: Maturing된 기술들의 제조 공정 표준화와 임상 데이터 축적이 핵심 변수. 특히 LVNPs의 추가 in vivo validation, HiST의 추가 암종 적용, Casgevy 승인 후 실제 임상 성적 데이터가 관전이다.

*출처: [Haldrup LVNPs CRISPR RNP Nucleic Acids Research 2023](https://consensus.app/papers/details/988a44b8b89e5d03a67fd82b85cebcd7/), [Cetin CRISPR Clinical Trials Expert Reviews Molecular Medicine 2025](https://consensus.app/papers/details/7e3e6068dcc7526f92d729fcd73cd99d/), [Fakiyesi CRISPR Cardiovascular Cureus 2026](https://consensus.app/papers/details/a52297053cfa5471bfa03ab5f8f01db4/), [Chen LLM Molecular Design Drug Discovery Today 2026](https://consensus.app/papers/details/6d5447b842e65298b7932fe7c4bf3e3c/), [Wei Perturbation Benchmark Nature Methods 2025](https://consensus.app/papers/details/2252f23023815170ad69618a33936f87/), [Ahlmann-Eltze Deep Learning Perturbation Nature Methods 2025](https://consensus.app/papers/details/a48c95b391f25de2813ae2d2bc322524/), [Yin AlphaFold3 Applications Frontiers Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/), [Abramson AlphaFold3 Nature 2024](https://consensus.app/papers/details/48c459ae935b59ea9a75d3647ba7d47b/), [Chakraborty AlphaFold3 Nature Biotechnology 2026](https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/), [Weng Frozen scFM Confidence Audit bioRxiv 2026](https://consensus.app/papers/details/530d9bca4dcd5352a22a7358413c9999/), [Chakraborty CRISPR Therapeutics Approval Molecular Therapy Nucleic Acids 2026](https://consensus.app/papers/details/68148f0062ec554ba4af1996dd3718cb/), [Oo FDA Platform AI J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Li HiST Spatial Transcriptomics Advanced Science 2026](https://consensus.app/papers/details/5dfa277e84425924aac9d148317c0bb7/), [Gao Gastric Cancer LAR Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/), [Li Pan-Cancer Niche Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)*

*#MaturingDay #Summary #Haldrup #LVNPs #RNPDelivery #Cetin #Casgevy #ClinicalTrials #Chen #LLM #MolecularDesign #DMTA #Wei #PerturbationBenchmark #PerturbNet #GeneralizationFailure #AhlmannEltze #DeepLearning #LinearBaselines #NoOutperformance #Yin #AlphaFold3 #ESMFold #Abramson #ProteinLigand #Chakraborty #AlphaFold3Evolution #Weng #ConfidenceAudit #MSP #Chakraborty #Casgevy #Approval #Oo #PlatformAligned #AIAnalytics #Li #HiST #AdvancedScience #Histology #SpatialGEPs #Gao #LAR #GastricCancer #Li #Niche4 #Niche11 #Maturing #ManufacturingStandardization #QualityValidation #ClinicalData #BiomedicalAI #DailyReport*

---

## Sources

[1] [Haldrup et al. — Engineered lentivirus-derived nanoparticles (LVNPs) for delivery of CRISPR/Cas ribonucleoprotein complexes supporting base editing, prime editing and in vivo gene modification. Nucleic Acids Research 2023](https://consensus.app/papers/details/988a44b8b89e5d03a67fd82b85cebcd7/)
[2] [Cetin et al. — Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects. Expert Reviews in Molecular Medicine 2025](https://consensus.app/papers/details/7e3e6068dcc7526f92d729fcd73cd99d/)
[3] [Fakiyesi et al. — CRISPR-Based Genome Editing in Inherited Cardiovascular Diseases: Therapeutic Advances, Emerging Editing Platforms, and Translational Challenges. Cureus 2026](https://consensus.app/papers/details/a52297053cfa5471bfa03ab5f8f01db4/)
[4] [Chen et al. — Large language models for molecular design: bridging the gap between chemical syntax and biological semantics. Drug Discovery Today 2026](https://consensus.app/papers/details/6d5447b842e65298b7932fe7c4bf3e3c/)
[5] [Wei et al. — Benchmarking algorithms for generalizable single-cell perturbation response prediction. Nature Methods 2025](https://consensus.app/papers/details/2252f23023815170ad69618a33936f87/)
[6] [Ahlmann-Eltze et al. — Deep-learning-based gene perturbation effect prediction does not yet outperform simple linear baselines. Nature Methods 2025](https://consensus.app/papers/details/a48c95b391f25de2813ae2d2bc322524/)
[7] [Yin et al. — Protein structure prediction powered by artificial intelligence: from biochemical foundations to practical applications. Frontiers in Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/)
[8] [Abramson et al. — Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 2024](https://consensus.app/papers/details/48c459ae935b59ea9a75d3647ba7d47b/)
[9] [Chakraborty, Bhattacharya & Lee — The transformative impact of AI-enabled AlphaFold 3: evolution, current status, and future prospects. Nature Biotechnology 2026](https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/)
[10] [Weng et al. — Cross-domain confidence reliability and remappability of frozen single-cell representations. bioRxiv 2026](https://consensus.app/papers/details/530d9bca4dcd5352a22a7358413c9999/)
[11] [Chakraborty et al. — CRISPR-Cas9-mediated therapeutics: Current clinical trials and therapy approval landscape to treat human diseases. Molecular Therapy. Nucleic Acids 2026](https://consensus.app/papers/details/68148f0062ec554ba4af1996dd3718cb/)
[12] [Oo et al. — FDA Gene Therapy Approvals (1998–2025): Current Status, Regulatory Evolution, and Future Directions. J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/)
[13] [Li et al. — HiST: Histological Images Reconstruct Tumor Spatial Transcriptomics via MultiScale Fusion Deep Learning. Advanced Science 2026](https://consensus.app/papers/details/5dfa277e84425924aac9d148317c0bb7/)
[14] [Gao et al. — A spatially resolved atlas of gastric cancer characterises a lymphocyte-aggregated region. Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/)
[15] [Li et al. — Pan-cancer analysis of spatial transcriptomics reveals heterogeneous tumor spatial microenvironment. Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)